Published on behalf of Pentraxin Therapeutics
Pentraxin Therapeutics Ltd is a University College London (UCL) spin out company founded in 2001 by Professor Sir Mark Pepys FRS FMedSci, Director of the Wolfson Drug Discovery Unit in the Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, at UCL’s Royal Free Campus. We are seeking to recruit an experienced Research Technician to provide expert technical support for an exciting new project to investigate macrophage function in systemic amyloidosis. The post‑holder will be responsible for isolation of human peripheral blood mononuclear cells (PBMCs) and purified monocytes, perform other cell biological and immunocytochemical experiments designed to analyse the functional activity of macrophages, and provide general laboratory and administrative support.
Successful candidates must have expertise in preparing human PBMCs and monocytes, in aseptic cell culture technique, and in immunocytochemistry or immunohistochemistry, with the ability to work to a meticulous standard. They will have excellent knowledge of and a background in contemporary cell biology, with relevant experience in providing technical support. Experience in multicolour flow cytometry for human monocyte phenotyping is desirable. Successful candidates will also be highly motivated and enthusiastic, with excellent organisational, interpersonal, and oral and written communication skills.
The salary range is £20,400-£31,656 plus London Allowance of £2,948, commensurate with skills, qualifications and experience. This is a fixed‑term post funded for 2 years in the first instance, and is based in the Wolfson Drug Discovery Unit’s Amyloid Fibril‑Cell Biology and Amyloid Fibril Cell‑Culture Laboratories (Class II containment).
Full details of the post including a job description and person specification can be accessed via the links below.
For informal enquiries about the post please contact Dr Glenys Tennent; email: email@example.com; telephone: 020 7433 2806.
The closing date for applications is 21 March 2016.
Pentraxin Therapeutics Ltd is an equal opportunities employer.